Drug Discovery and Development Solutions for Inflammatory Bowel Disease

Our In Vitro Efficacy Testing Service accelerates Inflammatory Bowel Disease (IBD) drug discovery by providing robust, sensitive screening and characterization platforms. We utilize advanced fluorescent, hemoglobin capture, and RNA quantification assays to assess compound effects on key IBD pathways, including cytokine signaling and epithelial barrier integrity. Our comprehensive methodology measures critical pharmacological parameters such as EC-50, IC-50, MEC, and MIC, ensuring precise evaluation of potency, efficacy, and safety. By targeting relevant proteins and biomarkers, our service delivers actionable data to optimize lead selection, dose determination, and therapeutic development for innovative IBD treatments.

Ace Therapeutics provides comprehensive animal model development services for Inflammatory Bowel Disease, leveraging 79 validated models across multiple species and strains. Our capabilities span chemically-induced, genetically engineered, infection-based, dietary, and advanced organoid/organ-on-chip methodologies. We offer turnkey solutions from study design and model induction to longitudinal monitoring and detailed molecular, cellular, and microbiome analysis. Clients benefit from expert guidance, rigorous quality control, and translationally relevant data to accelerate drug discovery, mechanistic studies, and preclinical evaluation. Our flexible, client-focused approach ensures tailored support, enabling efficient, reproducible, and scientifically robust advancement of IBD research and therapeutic development.

Our PK/PD research service for Inflammatory Bowel Disease provides comprehensive analysis of drug exposure and therapeutic response using advanced methodologies. We offer diverse administration routes, extensive compartment analysis in relevant tissues, and cutting-edge analytical techniques such as HPLC, LC-MS, and ELISA. Supported by a wide range of validated animal models, our studies deliver critical insights into ADME properties, concentration-effect relationships, and dosing optimization. This integrated approach enables data-driven decisions, accelerates drug development, and supports regulatory submissions, ensuring enhanced efficacy and safety of IBD therapies for successful clinical progression and transformative treatment outcomes.

Ace Therapeutics provides comprehensive in vivo toxicity assessment services tailored for Inflammatory Bowel Disease (IBD) drug development. Utilizing advanced animal models, state-of-the-art analytical technologies, and GLP-compliant protocols, our studies encompass acute, chronic, organ-specific, and specialized toxicity evaluations. We integrate IBD-relevant endpoints, including colon histopathology and immune profiling, to ensure translational relevance. Our multidisciplinary team delivers precise, reproducible data aligned with international regulatory standards, enabling robust safety characterization. By offering a holistic, scientifically rigorous approach, Ace Therapeutics empowers partners to advance IBD therapies with confidence, supporting informed decision-making and seamless progression toward clinical success.

Ace Therapeutics offers exploratory biomarker analysis services for preclinical Inflammatory Bowel Disease research, utilizing multi-omics discovery approaches and advanced analytical platforms. We investigate and screen molecular candidates across genomics, transcriptomics, proteomics, and metabolomics, enabling comprehensive evaluation of targets with potential as IBD biomarkers. Our methodologies encompass high-throughput screening, rigorous candidate assessment, and assay development tailored to specific research objectives. Emphasizing technical expertise and stringent quality control, we support the scientific exploration of biomarker candidates, focusing on their relevance to disease mechanisms, therapeutic response, and immune regulation, while maintaining an objective, research-driven approach without clinical diagnostic claims.